Selfdiagnostics SARS-CoV-2 IgM/IgG Antibody Assay Kit is a rapid, accurate and straightforward point-of-care test kit that qualitatively detects IgM and IgG antibodies against the virus that causes COVID-19.

The test detects specific SARS CoV2 IgG and IgM antibodies in the blood in response to a coronavirus infection.

The detection of antibodies can be used to identify those who have already had contact with the virus. IgG may remain elevated for up to several months and possibly years, which could help determine who has been exposed to the coronavirus, even if a person did not exhibit any symptoms of the COVID-19 disease.

Furthermore, the test can be useful concerning contact tracing and serological surveillance at local, regional and national level.

While molecular testing detects whether someone is infected with the virus, antibody tests can determine whether one has developed an immunoreaction to COVID-19. In updated guidelines published on 30th June, The Swedish Public Health Agency said that based on current knowledge, a positive test with all likelihood means that the person is protected from reinfection for up to six months from the date of receiving a positive result. This assessment may change as further research is done on the coronavirus and its antibodies.

The above statement indicates that a person with SARS CoV2 antibodies in their blood has a lower risk of getting re-infected with COVID-19 and may bear a lower risk of spreading the infection.

Selfdiagnostics SARS-CoV-2 IgM/IgG Antibody Assay Kit has already been widely tested. In studies with clinical samples, it showed 99% specificity and cross-reactivity tests excluded false-positive results with previous endemic human coronavirus antibodies (HKU1, OC43, NL63 and 229E). Tests with capillary blood showed comparable results as with venipuncture whole blood, serum and plasma.

Selfdiagnostics SARS-CoV-2 IgM/IgG Antibody Assay Kit test kit does not require any special equipment which makes it an ideal screening and triage tool for doctors, nursing homes, clinics doctors and Covid-19 wards in hospitals.  The test is completed in three simple steps.

  1. First, a sample is collected from finger-stick or venipuncture whole blood, plasma or serum.
  2. A sample is then transferred to the test cassette, followed by two drops of a buffer solution.
  3. The results can be read after 15 minutes.

About Selfdiagnostics Deutschland

Selfdiagnostics Deutschland GmbH was founded in 2012 by entrepreneurs and scientists to develop new, easy to use, precise and low-cost rapid Point-Of- Care tests to detect a wide array of different diseases.  Selfdiagnostics offers the world’s smallest application of PCR technology to create tests that you can use in the comfort of your own home, without the need to visit a doctor.

For more information:

Harri Peiker, Chief Operating Officer
Selfdiagnostics Deutschland GmbH
Phone: +49 341 355 238 511
e-mail: harri.peiker@selfdiagnostics.com